论文部分内容阅读
目的对比观察泮托拉唑与雷尼替丁治疗十二指肠溃疡的临床疗效及用药安全性。方法 134例活动性十二指肠溃疡患者按前瞻性随机化原则分为观察组和对照组各67例,观察组服用泮托拉唑40 mg,1次/d;对照组应用雷尼替丁150 mg,2次/d,两组均同时应用抗Hp及保护胃黏膜等常规治疗,两组均4周为1个疗程。结果两组治疗后临床症状均有不同程度好转,观察组溃疡愈合率89.55%(60/67),总有效率为100%;对照组溃疡愈合率53.73%(36/67),总有效率为86.57%(58/67),两组比较差异有统计学意义(P<0.01)。两组治疗期间均未出现明显不良反应,用药安全。结论在抗Hp及保护胃黏膜等常规治疗基础上加用泮托拉唑治疗活动性十二指肠溃疡显示出良好的临床效果,具有疗程短、疗效好、临床愈合率和Hp根除率高,不良反应少,患者耐受性好等优点,值得临床推广应用。
Objective To compare the clinical efficacy and medication safety of pantoprazole and ranitidine in the treatment of duodenal ulcer. Methods A total of 134 patients with active duodenal ulcer were randomly divided into observation group (67 cases) and control group (67 cases). Patients in observation group were treated with pantoprazole 40 mg once daily, while in control group, ranitidine 150 mg twice a day. Both groups were treated with conventional anti-Hp and gastric mucosal protection. Both groups were given a course of 4 weeks. Results The clinical symptoms of both groups improved to some extent after treatment. The healing rate of ulcer in the observation group was 89.55% (60/67) and the total effective rate was 100%. The healing rate of ulcer in the control group was 53.73% (36/67), the total effective rate was 86.57% (58/67), the difference between the two groups was statistically significant (P <0.01). No significant adverse reactions during the two groups during treatment, medication safety. Conclusions The application of pantoprazole to active duodenal ulcer on the basis of routine therapy such as anti-Hp and protective gastric mucosa shows good clinical effect, short course of treatment, good curative effect, high clinical healing rate and high Hp eradication rate, Less adverse reactions, good patient tolerance and other advantages, it is worthy of clinical promotion and application.